Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Agilect Is "Approvable" For Second Time

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA continues to have concerns about issues raised in last year's approvable letter for the Parkinson's agent, Teva said.

You may also be interested in...



Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks

Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.

Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks

Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.

FDA Extends Agilect User Fee Deadline Due To “Technical Error”

FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel